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Background and Purpose: The lack of selective sodium–calcium exchanger (NCX)
inhibitors has hampered the exploration of physiological and pathophysiological roles
of cardiac NCX 1.1. We aimed to discover more potent and selective drug like NCX
1.1 inhibitor.
Experimental Approach: A flavan series-based pharmacophore model was con-
structed. Virtual screening helped us identify a novel scaffold for NCX inhibition. A
distinctively different NCX 1.1 inhibitor, ORM-11372, was discovered after lead opti-
mization. Its potency against human and rat NCX 1.1 and selectivity against other ion
channels was assessed. The cardiovascular effects of ORM-11372 were studied in
normal and infarcted rats and rabbits. Human cardiac safety was studied ex vivo using
human ventricular trabeculae.
Key Results: ORM-11372 inhibited human NCX 1.1 reverse and forward currents;
IC50 values were 5 and 6 nM respectively. ORM-11372 inhibited human cardiac
Abbreviations: Amax, maximum amplitude of action potential; AP, action potential; APD90, action potential duration 90%; clogP, calculated logarithm of partition coefficient; clogS, calculated
logarithm of solubility; CM, cardiomyocyte; ECC, excitation–contraction coupling; FCCP, carbonyl cyanide 4-(trifluoromethoxyl); HAM F-12, Ham's Nutrient Mixture F-12; HIPAA, Health
Insurance Portability and Accountability Act; hiPSC, human-induced pluripotent stem cell; hSCN5, human sodium voltage-gated channel subunit 5; ICaL, L-type Ca
2+ channel current; IhERG, human
ether-á-go-go-related gene-encoded voltage-dependent potassium channel current; IMR-32, human neuroblastoma cell line; INa, human cardiac NaV1.5 channel current; INCX, Na
+/Ca2+
exchanger current; IRB, institutional review board; LQT, long QT time; LV + dP/dtmax, left ventricular inotropic effect; LV − dP/dtmin, left ventricular relaxation; LVP, left ventricular pressure; m,
meta position; MEM, minimum essential medium; MI, myocardial infarction; MRSA, methicillin-resistant Staphylococcus aureus; NC3Rs, National Centre for the Replacement, Refinement &
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sodium 1.5 (INa) and hERG KV11.1 currents (IhERG) in a concentration-dependent man-
ner; IC50 values were 23.2 and 10.0 μM. ORM-11372 caused no changes in action
potential duration; short-term variability and triangulation were observed for concen-
trations of up to 10 μM. ORM-11372 induced positive inotropic effects of 18 ± 6%
and 35 ± 8% in anaesthetized rats with myocardial infarctions and in healthy rabbits
respectively; no other haemodynamic effects were observed, except improved relaxa-
tion at the lowest dose.
Conclusion and Implications: ORM-11372, a unique, novel, and potent inhibitor of
human and rat NCX 1.1, is a positive inotropic compound. NCX inhibition can induce
clinically relevant improvements in left ventricular contractions without affecting
relaxation, heart rate, or BP, without pro-arrhythmic risk.
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1 | INTRODUCTION
The sodium–calcium exchangers (NCX; SLC8) play dynamic roles in
excitation–contraction coupling (ECC) in cardiomyocytes (CMs). The
driving force of NCX depends on sodium and calcium concentrations
across the cell membrane cell as, well as the membrane potential.
NCX operates dominantly in the forward mode (Ca2+ extrusion and
inducing depolarizing current) during systole in all species. Therefore,
selective NCX inhibitors have only minor effect on peak [Ca2+]i in
mice and dogs (Kohajda et al., 2016; Kormos et al., 2014; Oravecz
et al., 2018). In addition, both mechanical relaxation and [Ca2+]i decay
remained unchanged (Kormos et al., 2014). Selective NCX inhibitors
either slightly shorten action potential (AP) duration or have no effect
in normal oxygen and ionic conditions. Overall, it seems that selective
inhibition of NCX exerts minimal effecst on intracellular Ca2+ or action
potential duration (APD) under normal conditions.
In heart failure, the intracellular Ca2+ concentration balance is
changed, and the role of NCX becomes even more important (Bers &
Despa, 2006). In addition, NCX and intracellular Ca2+ regulate each
other and affect cardiac remodelling, as recently described
(Primessnig et al., 2019). ORM-11035, a selective NCX inhibitor,
attenuated cardiac hypertrophic remodelling and prevented cardiac
dysfunction in rats exhibiting heart failure. NCX also reportedly con-
trols the heart rate (HR) through its effects on the sinus and atrioven-
tricular nodes (Kaese et al., 2017). In sinus node, the funny current (If)
and the NCX current (INCX) together establish a strong depolarization
capacity providing an important safety factor for stable pacemaking
(Kohajda et al., 2019). NCX also plays a role in BP control in normo-
tensive and hypertensive individuals (Zhang, 2013).
The solute carrier transporter gene family (SLC8) encodes several
Na+/Ca2+ exchanger subtypes. SLC8A1 gene overexpression and
NCX1.1 protein up-regulation are linked to many pathological condi-
tions that lead to reduced contractility and arrhythmias
(Khananshvili, 2013). NCX is organized into 10 transmembrane seg-
ments and is localized in the sarcolemmal membrane (Jost et al., 2013;
Shattock et al., 2015). Two Ca2+ binding domains are known currently.
Their activation is regulated by Ca2+ binding at these sites, whereas
Na+ binding leads to NCX inactivation (Hilgemann, Matsuoka, Nagel,
& Collins, 1992).
Several potent NCX inhibitors have been reported (Table S1). In
1996, KB-R7943 was the first NCX inhibitor to be discovered. SN-6
(Iwamoto et al., 2004) and SEA0400 (Matsuda et al., 2001) were
reported to be more selective NCX inhibitors than KB-R7943. YM-
244769 (Iwamoto & Kita, 2006), which was discovered in 2006, was
reported to be a novel NCX inhibitor with higher selectivity. ORM-
10103 (Koskelainen, et al., 2003) was discovered early, followed by
ORM-10962 (Otsomaa, et al., 2004) and GYKB-6635 (Geramipour
What is already known
• NCX plays a pathological role in heart failure, cardiac
ischaemia, and arrhythmia.
• Known NCX modulators are unselective small molecules
or peptides.
What this study adds
• The new NCX inhibitor ORM-11372 was the most
potent and selective inhibtor described so far.
• ORM-11372 exerted positive inotropic effects in rabbits,
without pro-arrhythmic risk in human cardiac tissue.
What is the clinical significance
• ORM-11372 exerted positive inotropic effect without
other haemodynamic effects.
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et al., 2016) and all three were highly selective NCX inhibitors (Jost
et al., 2013; Kohajda et al., 2016). Despite their higher selectivity,
their use as positive inotropic tool compounds in experiments in vivo
was prevented by their poor solubility (solubility of SEA0400 is less
than 10 μg ml-1 in pH 7.4 phosphate buffer which places it in the solu-
bility class “insoluble”). ORM-10962 is an exception from previously
reported selective NCX inhibitors, as it exhibits reasonable solubility
in in vivo studies.
Here, we describe the discovery of a new type of positive inotro-
pic compound, ORM-11372, exhibiting high selectivity for NCX1.1
and provide its pharmacological profile in vitro, in vivo, and ex-vivo in
human ventricular trabeculae. ORM-11372 was developed for acute
short-term use with fast clearance.
2 | METHODS
2.1 | Discovery of a novel chemical series
A novel and unique chemical series was discovered using ligand-based
pharmacophores for virtual screening with Catalyst (Accelrys)
(Figure 1a). Pharmacophore features used for virtual screening were
derived from previously discovered NCX1 inhibitor flavan structures,
such as ORM-10103 (Koskelainen et al., 2003) and ORM-10962
(Otsomaa et al., 2004). Based on the results of virtual screening, a pro-
posed library with 636 commercially available compounds was
selected for testing in the fluorescence-based assay, at concentrations
of 10 μM. The original hit ORM-120407 inhibited NCX1.1 by 87%
and had an IC50 value of 200 nM. It inhibited human ether-á-go-go-
related gene (hERG) and L-type Ca2+ channels, with IC50 values of 2.1
and 3.1 μM respectively. These results indicated that the scaffold
exhibited optimization potential. The structure–activity relationship
(SAR) of ORM-120407 was explored further leading to the discovery
of ORM-11372 (Table 1 and Figure 2), was discovered during medici-
nal chemistry optimization.
An analysis of 250 previously discovered NCX inhibitor compounds
by Orion (Koskelainen et al., 2003; Otsomaa et al., 2004) resulted in a
five-feature pharmacophore, which was used for the virtual screening
of Cambridge and Specs compound libraries. In silico hits were further
filtered based on predicted activity, calculated logarithm of solubility
(clogS), calculated logarithm of partition coefficient (clogP), and diver-
sity. The substructure features were optimized in parallel processes,
and beneficial structural features were merged, in order to identify the
potential overall synergistic effects for NCX1.1 inhibition. Representa-
tive samples of 135 synthesized derivatives are presented in Figure 2.
The hydrogen bond donor property of aniline in the original hit
molecule ORM-120407 was proven to be important for NCX1.1
activity in the scaffold. The addition of polar substituents was not tol-
erated in the A ring, but halogen substitution on the p and m positions
was tolerated and resulted in improved NCX1 inhibition. However,
neither position was favoured over the other nor showed synergistic
or additive effects. Their selectivity towards the hERG channel was
found to be its differentiating property.
SAR tolerated five-membered B-ring systems better than six-
membered systems. Ring heteroatoms, that is, oxygen or nitrogen
molecules at position 1 (of furan) in combination with a
1,5-substitution, were proven to be critical for binding; that is, a car-
bon at position 1 abolished activity. This finding indicates that the
presence of a hydrogen bond acceptor at that position is important. B-
ring optimization provided three potential ring systems that were tol-
erated: furans, oxazoles, and thiazoles. Two latter systems tolerated
4,2-substitution and 2,4-substitution, while the three heteroatoms in
the B-ring reduced NCX1 inhibition activity. Though ORM-120407
showed good inhibitory activity towards NCX1, its selectivity towards
hERG (2.1 μM) and L-type calcium (3.1 μM) channels needed to be
improved. ORM-120407 also had poor solubility (<10 μgml−1). ORM-
F IGURE 1 The upper part of the figure shows the
pharmacophore model used for virtual screening. In silico hits were
further filtered based on predicted activity, calculated logarithm of
solubility (clogS), calculated logarithm of partition coefficient (clogP),
and diversity. The middle part displays the hit structure and
substructure features optimized in parallel processes. At the bottom
of the figure, two routes used for the synthesis of the compounds are
presented, namely, (1) reductive amination and (2) alkylation under
basic conditions
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11298 exhibited better inhibitory activity towards NCX1 and good
selectivity towards hERG channels. The oxazole series also exhibited
good selectivity towards L-type calcium channels such as ORM-
11298, but many derivatives were chemically unstable. The substitu-
tion of the C-ring phenyl was unnecessary, but some substituents such
as aniline and chlorine were tolerated. The replacement of the phenyl
ring with different heteroaromatic ring systems was mainly tolerated.
2.2 | Synthesis
Most compounds were prepared via reductive amination (Figure 1c,
Route 1), except for ORM-11298 and ORM-11863, which were
prepared by aniline alkylation (Figure 1c, Route 2). The reaction
between the aniline and carbaldehyde derivatives could occur in the
presence of a strong acid at elevated temperatures. The reduction
of the imine intermediate could be carried out using a suitable
reducing agent, such as sodium borohydride (NaBH4). The alkylation
reaction in Route 2 is performed in the presence of a base. The
products were isolated from the reaction mixture by extraction with
ethyl acetate, followed by evaporation. The starting materials used
in the processes were either commercially available or could
be prepared via synthetic routes (Parry, Bryce, & Tarbit, 2003;
Ye et al., 2010). ORM-11372 was synthesized via the reductive
amination of 5-(3-nitrophenyl)furan-2-carbaldehyde with the
corresponding fluoroaniline, followed by the hydrogenation of the
TABLE 1 NCX inhibition values, as
IC50, and the selectivity profile towards
hERG and L-type Ca2+ channels for
selected compounds
Compound NCX IC50 (nM) hERG IC50 (μM) L-type Ca2+ IC50 (μM) Solubility class
ORM-120407 231 2.1 3.1 Insoluble
ORM-11023 156 — — —
ORM-11024 875 — — —
ORM-11165 4 9 2 Insoluble
ORM-11217 210 14.6 — Moderate
ORM-11190 204 — — —
ORM-11298 31 >10 — Moderate
ORM-11372 6 10.6 6.1 Moderate
ORM-11817 3 2.4 10.4 Insoluble
ORM-11863 2.5 — — Insoluble
ORM-11875 90 — — Moderate
The data shown are mean IC50 values from n=3 assays for NCX, n=4 assays for hERG and n=4 assays for
L-type Ca2+ channels. Each assay represents results from an independent plate. Abbreviations: hERG,
human ether-á-go-go-related gene; n, number of independent plates; NCX, sodium–calcium exchanger.
F IGURE 2 Illustrative chemical
structures (out of 135 synthesized
molecules) during the chemical
optimization of the scaffold. ORM-
11372 had the most favourable profile
overall, out of the synthesized
derivatives
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nitro group under mild conditions. Details of experiments can be
found in Figures S1–S14.
2.3 | Cell lines and cell culture
Spodoptera frugiperda (Sf9; RRID:CVCL_0549) cells are widely used for
the transient and stable expression of recombinant proteins. Here, Sf9
cells were stably transfected with human NCX 1.1 and maintained in
spinner flasks with insect cell culture medium (TNM-FH), sup-
plemented with 10% FBS, antibiotic–antimycotic solution, and
50 μgml−1 of blasticidin at 28C in a non-humidified, CO2-free atmo-
sphere. The Sf9 cell suspension was subcultured three times a week.
Human-induced pluripotent stem cell (hiPSC)-derived CMs
(Cor.4U CMs; RRID:CVCL_Y550) were thawed, seeded onto gelatine-
coated coverslips, and maintained, as described in the manufacturer's
protocol. Cor.4U cells express cardiac proteins including NCX1 and
exhibit the relevant electrophysiology, demonstrating an ability to
model human cardiac responses to drugs (Blinova et al., 2017; Huo
et al., 2017).
CHO cells stably expressing either hERG1a (KV11.1) channels
(KCNH2; RRID:CVCL_H512) or human 5-HT2B receptors were cul-
tured at 37C in a 5% CO2/95% air atmosphere in the Ham's Nutrient
Mixture F-12 (HAM F-12) medium supplemented with 10% FBS (heat
inactivated), 100 μgml−1 of hygromycin B (Invitrogen), and
100 μgml−1 of geneticin or 100 IUml−1 of penicillin and 100 IUml−1
of streptomycin, 25-mM HEPES, 500 μgml−1 of geneticin, and
250 μgml−1 of Zeocin®. Adhered cells were detached using either
Detachin® solution or trypsin and replated twice a week. HEK
293 (RRID:CVCL_0045) and IMR-32 cells (CCL-127; RRID:CVCL_
0346) were cultured similarly but maintained instead in DMEM, sup-
plemented with 10% FBS (heat inactivated), 100 IUml−1 of penicillin
and 100 IUml−1 of streptomycin, and 25-mM HEPES, and in the case
of the IMR-32 cell line, with minimum essential medium (MEM) non-
essential amino acids. IMR-32 cells are derived from a human neuro-
blastoma and endogenously express L-type (CaV1.x) calcium channel
(Sher, Gotti, Pandiella, Madeddu, & Clementi, 1988).
The hERG-encoded voltage-dependent potassium channel cur-
rent (IhERG) cells to be studied were harvested with Detachin solution
and either diluted with a volume of CHO cell serum-free media (sup-
plemented with 100 IUml−1 of penicillin/streptomycin and 25-mM
HEPES) to obtain cells, for which the cell density was 4 x106
cellsml−1, or plated on glass coverslips and used on the following
1–2 days. HEK 293 cells were transiently transfected using
lipofectamine (Invitrogen, USA), with a human sodium voltage-gated
channel subunit 5 (hSCN5) A (transcript variant 2)-containing plasmid,
in Optimem medium. After a 5-h incubation period, the transfection
medium was replaced with the normal growth medium. The cells were
harvested by trypsinization, centrifuged and resuspended in the
appropriate extracellular solution for performing studies the next day.
CHO–5-HT2B cells were plated into 96-well plates on the previous
day, at a density of 4 x104 cells per well, with a modified version of
the growth media.
2.4 | Rat ventricular CMs
2.4.1 | Animals
All animal care and experimental procedures complied with the Guide
for the Care and Use of Laboratory Animals (USA NIH publication No
85–23, revised 1996), and were approved by the Csongrád County
Governmental Office for Food Safety and Animal Health, Hungary
(approval No.: XIII/1211/2012). Animal studies are reported in com-
pliance with the ARRIVE guidelines (Percie du Sert et al., 2020) and
with the recommendations made by the British Journal of Pharmacol-
ogy (Lilley et al., 2020). Six-week old male Wistar rats (200-250;
RRID:RGD_13508588, obtained from a licensed supplier Toxi-coop
Ltd. Hungary) were used in this study.
2.4.2 | Housing and husbandry
The rats were maintained in standard rat cages (380 × 270 × 200 mm;
1,025 cm2). The number of cage companions was four animals per
cage. Cages were equipped with external bottle top-type lids with
half-pocket wire bar lid feeders. The bedding of the cage floor was
composed of aspen chips (Innovo Ltd., Hungary). The room tempera-
ture of the animal house was kept constant at 23C, with a humidity
of 40–65%. Twelve hours of dark–light cycle was applied with a low
light intensity. Food (obtained from Innovo Ltd., Hungary) and tap
water were provided ad libitum to the animals. The tap water is regu-
larly checked for any pathogens.
2.4.3 | Cell preparation
Rats were anaesthetized with sodium thiopental (0.1 gkg−1, i.p.) and
injected with heparin sodium (500 IU, i.v.). Hearts were rapidly
excised, mounted via the aorta on a Langendorff apparatus, and retro-
gradely perfused at 37C with the Krebs–Henseleit solution for 5 min,
with Krebs-Henseleit solution (composition (in mM): 118.5 NaCl,
4 KCI, 2 CaCl2, 1 MgSO4, 1.2 NaH2PO4, 25 NaHCO3, and 11.1 glu-
cose), pH 7.4 when saturated with a mixture of 95% O2 and 5% CO2.
The perfusion of the heart was continued using Ca2+-free Krebs–
Henseleit solution for 10 min, and completed by the addition of
0.05% collagenase (type I), 0.05% hyaluronidase, and 200-μM CaCl2,
for a further 10 min. Subsequently, the left ventricular myocardium
was minced and gently agitated. Dissociated cells were stored at room
temperature in a solution containing (in mM) 89 KOH, 70 glutamate,
15 taurine, 30 KCI, 10 KH2PO4,10 HEPES, 0.5 MgCl2, 11 glucose, and
0.5 EGTA, and the pH was set to 7.3 using KOH. Cardiomyocytes
were rod shaped and showed a clear striation, when external calcium
levels were restored. One drop of the cell suspension was placed in a
recording chamber and mounted on the stage of an inverted micro-
scope (Olympus IX51, Olympus, Japan), and the individual myocytes
were allowed to settle and adhere to the bottom of the chamber for
at least 5 min before initiating superfusion.
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2.5 | Fluorescence screening assay for hNCX 1.1
inhibition
NCX reverse mode activity was stimulated via a 50% dilution of the
extracellular Na+ level using the internal pipettor of FLEXstation, a fluo-
rescence imaging plate reader (Molecular Devices, USA), while simulta-
neously monitoring intracellular calcium levels. After dilution, the
concentration of other ions remained the same, but Na+ concentration
was diluted to the half of original concentration of 172 to 86 mM. For
Sf9 insect cells, normal extracellular Na+ ion concentration is 172 mM.
Typically, 50 μl of a solution containing 150,000–200,000 Sf9–NCX cells
was loaded onto each well of a 96-well plate. Cells were preincubated
with the intracellular calcium dye Fluo-4 and Fluo-6, and the concentra-
tions of the test compound (three replicates) were determined for about
1 h at room temperature before experimentation. The extracellular solu-
tion contained (in mM) 172 NaCl, 10 HEPES, 1 CaCl2, 1.2 MgCl2, 0.33
NaH2PO4, 5 glucose, and 5 probenecid. The pH was adjusted to 7.4 with
NaOH. The extracellular Na+ was diluted by the addition of a Na+-free
extracellular solution (containing in mM: 147 N-methyl-D-glucamine
(NMDG), 10 HEPES, 1 CaCl2, 1.2 MgCl2, 0.33 NaH2PO4, and 5 glucose
with the pH adjusted by HCl to 7.4)-induced robust and reproducible
elevation of intracellular calcium. The osmolarity of both solutions was
adjusted to 340–355 mOsm in order to match the Sf9 cell media osmo-
larity. In each plate, the IC50 determination for each test compound was
based on relative fluorescence changes in comparison with control and
5-mM nickel acetate-induced NCX inhibition.
2.6 | Confirmatory fluorescence assay for hNCX
1 inhibition
A confirmatory hNCX1 inhibition assay was performed in Charles River
Laboratories, Cleveland. Briefly, HEK293 cells stably expressing hNCX1
were plated in 384-well black wall, clear-bottom microtitre plates and
the next day loaded with Fluo-8 for 30 min at 37C. A plate was inserted
into a FLIPRTETRA, and a baseline was recorded during a preincubation
period where test compound or vehicle in a Na+-free HB-PS containing
thapsigargin (6 μM) and carbonyl cyanide 4-(trifluoromethoxyl) (FCCP)
(30 μM) was added to each well for 5 min. Next, the NCX1 stimulation
period was recorded in which Na+-containing HB-PS (with 2-μM
thapsigargin and 10-μM FCCP) was added. The experiments were per-
formed at room temperature. The kinetic data generated were reduced
for each well to maximum relative fluorescence units (RFU) minus mini-
mum RFU after subtracting bias based on the first sample. The mean of
the max–min RFU values during the stimulation period for the 3–4 repli-
cates at each concentration on a plate was then plotted versus concen-
tration and fitted to a Hill equation.
2.7 | Fluorescence secondary screening assays
2.7.1 | L-type calcium channel inhibition
Undifferentiated IMR-32 cells were harvested, centrifuged, and
resuspended in a probenecid-Ringer solution consisting (in mM)
150 NaCl, 3 KCl, 1.2 MgCl2, 1 CaCl2, 20 HEPES, 5 glucose and 2.5
probenecid (pH 7.4 adjusted with NaOH, osmolarity 320–324 mOsm).
We added 0.04% Pluronic F-127 and Fluo-4 to this solution, and after
incubating the cells for 30 min at room temperature, these additives
were removed from the probenecid-Ringer solution by centrifugation
and resuspension. The cell suspension was pipetted (250,000 cells in
75 μl per well) into a 96-well plate, into which the test compound
(75 μl per well at 2,667 × the final concentration; five concentrations
with eight replicates) had already been added. The plate was cen-
trifuged once (5 min, at 287 x g) to ensure that the cells were moved
to the bottom of the wells. FLEXstation was then used to measure the
increase in intracellular calcium at 37C, following depolarization,
which was induced by the addition (50 μl per well) of a KCl-Ringer
solution containing (in mM) 200 KCl, 20 CaCl2, 1.2 MgCl2, 20 HEPES
and 2.5 probenecid respectively (pH adjusted to 7.4 with KOH, with
an osmolarity of 320–324 mOsm).
2.7.2 | 5-HT2B receptors
Changes in the intracellular calcium concentration of CHO–5-HT2B
cells in the probenecid-R inger were measured, using Fluo-4 or cal-
cium 3 dyes and the FLEXstation, at 37C. ORM-11372 was applied
at seven concentrations (four replicates), 10 s after the initiating the
measurement process in the agonist assay, but was preincubated
(at eight concentrations with three replicates) in the antagonist assay,
with 10-nM 5-HT added at the 10-s time point.
2.8 | Electrophysiology
Manual patch-clamp recordings of membrane currents (INCX, L-type Ca
2+
channel current [ICaL], human cardiac sodium 1.5 current [INa], and IhERG)
were undertaken using either an Axopatch 200B or Axopatch ID ampli-
fier (Molecular Devices, USA), using the whole-cell configuration. Cells
were at least initially (except when recording INa) perfused with an extra-
cellular solution consisting of (in mM) 143 NaCl, 4 KCl, 1.8 CaCl2, 1.2
MgCl2, 5 glucose, and 10 HEPES (pH 7.4 with NaOH; osmolarity
adjusted to 301 ± 3 mOsm). A slightly modified version was used for the
rat ventricular CMs (in mM: 144 NaCl, 0.4 NaH2PO4, 4.0 KCl, 1.8 CaCl2,
0.53 MgSO4, 5.5 glucose, and 5.0 HEPES). Patch pipettes were pulled
with a P-2000 or P-97 micropipette puller (Sutter Instruments, USA)
from borosilicate glass capillaries and had resistances of between 2 and
4 MΩ when filled with any of the pipette solutions (see below). The data
were filtered at 1 or 2 kHz and digitized at 10 kHz with acquisition and
analysis performed by use of pClamp software (Versions 8–10; Molecu-
lar Devices; RRID:SCR_011323).
2.8.1 | NCX current (INCX)
After the establishment of the whole-cell configuration with hiPSC-
derived CMs or rat ventricular myocytes, the extracellular solution
was switched to a K+-free bath solution as described earlier (Hobai,
Khananshvili, & Levi, 1997; Jost et al., 2013). The solution was
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composed of (in mM) 135 NaCl, 10 CsCl, 1 CaCl2, 1 MgCl2, 0.2 BaCl2,
0.33 NaH2PO4, 10 TEACI, 10 HEPES, and 10 glucose supplemented
with 20-μM ouabain, 50-μM lidocaine, and 1-μM nisoldipine or 2-μM
nitrendipine at pH 7.0 (osmolarity adjusted to 301 ± 3 mOsm). The
pipette solution contained (in mM) 140 CsOH, 75 aspartic acid,
20 TEACI, 5 MgATP, 10 HEPES, 20 NaCl, 20 EGTA, and 10 CaCl2
(pH adjusted to 7.2 with CsOH; osmolarity adjusted to 290 ± 2 mOsm).
The free intracellular Ca2+ level in the patch pipette was 140 nM
according to Maxchelator (RRID:SCR_000459) software (Bers, Patton,
& Nuccitelli, 2010).
The measurement of current in the K+-free bath solution using
a ramp voltage protocol at 20-s intervals represented the first con-
trol, after which values were measured in the presence of one or
more increasing concentrations of ORM-11372 and finally upon
exposure to 10-mM NiCl2. The voltage protocol consisted of volt-
age ramps (at a rate of 100 mVs−1) with a holding potential of
−40 to 60 mV, which changed to −100 mV and then returned to
−40 mV. INCX was defined as the Ni2+-sensitive current value.
However, for rat ventricular myocytes, the magnitude of the
inward current (forward mode) was particularly small and variable.
Therefore, to enhance the inward current and enable a solution
with a certain concentration of ORM-11372 to be measured, the
concentrations of the K+-free and pipette solutions were altered. In
the bath solution, the CaCl2 concentration was reduced to
0.5 mM, while in the pipetted solution, the NaCl and EGTA con-
centrations were decreased to 5 and 10 mM respectively. All
experiments were performed at 35–37C. The outward human INCX
inhibition current was measured at the following ORM-11372 con-
centrations: 3 (n = 4), 10 (n = 6), 30 (n = 4), and 100 (n = 3) nM.
The concentrations used for human inward INCX current measure-
ment were 3 (n = 4), 10 (n = 4), 30 (n = 3), and 100 (n = 2) nM.
The outward INCX current in rat CMs was measured at concentra-
tions ranging from 1 to 1,000 nM (n = 5). The inward INCX current
in rats was measured in additional experiments under changed con-
ditions, to enhance the inward INCX current. In these experiments
(n = 3), the effect of ORM-11372 was tested at a concentration of
10 nM, at which the IC50 and reverse INCX current values were
approximately equal.
2.8.2 | L-type calcium current (ICaL)
ICaL was recorded from hiPSC-derived CMs (at room temperature,
n = 2) and rat ventricular myocytes at 1 μM (n = 3; 5 cells) and at
10 μM (n = 4; 6 cells) in an extracellular solution supplemented with
4-aminopyridine (3 mM) at 37oC. The pipette solution used for hiPSC-
derived CMs consisted (in mM) (pH 7.2; osmolarity adjusted to
293 mOsm) 110 KCl, 40 KOH, 20 TEACI, 3 MgATP, 10 EGTA, and
5 HEPES. The composition of the pipette solution used for rat CMs
was (in mM) 125 CsCl, 20 TEACI, 5 MgATP, 10 EGTA, and 10 HEPES;
the pH was adjusted to 7.2 using CsOH. ICaL was evoked by a 400-ms
depolarization process to 0 mV from a holding potential of −40 mV
every 5 s or, in the case of the rat CMs, by 400 ms; depolarizations to
potentials ranging from −35 to 55 mV occurred after a prepulse to
−40 mV, from the holding potential of −80 mV.
2.8.3 | NaV1.5 channel current (INa)
Recordings were performed on HEK cells (n = 3) that transiently
expressed voltage-gated sodium channel alpha subunit 5 (SCN5A) at
room temperature, in a bath solution containing (in mM) (pH 7.4 with
NMDG; osmolarity adjusted to 300 ± 2 mOsm) of 40 NaCl, 97 L-
aspartic acid, 4 KCl, 1.8 CaCl2, 1 MgCl2, 10 glucose, and 10 HEPES.
The pipette solution contained (pH 7.2 with CsOH; osmolarity
adjusted to 270 ± 3 mOsm) 130 caesium methane sulfonate, 5 MgCl2,
5 EGTA, 0.1 GTP, 4 ATP disodium salt hydrate (Na2ATP), and
10 HEPES. The voltage protocol, which was repeated after each sec-
ond, included of the process of hyperpolarization, from a holding
potential of −80 to −120 mV for 200 ms, followed by that of depolar-
ization to −15 mV for 10 ms. The peak current values observed while
applying the test pulse at −15 mV were used for analysis.
2.8.4 | KV11.1 channel current (IhERG)
Values from hERG-expressing cells (n = 4) were recorded with the
standard extracellular solution at the physiological temperature and
a pipette solution containing (in mM) 130 KCl, 7 NaCl, 5 EGTA,
1 MgCl2, 5 Na2ATP, and 5 HEPES (pH was set to 7.2 with KOH;
osmolarity was adjusted to 290 ± 3 mOsm). IhERG was evoked
using a voltage protocol, which was repeatedly performed every
10 s, consisting of a depolarization step from the holding potential
of −75 to 10 mV for 500 ms, followed by a repolarization step to
−40 mV for 500 ms. The peak tail current values at −40 mV were
used for analysis.
In addition, after loading the CHO–hERG cell suspension, whole-
cell voltage-clamp values were recorded at room temperature on a
QPatch 16× automated patch-clamp (Sophion Biosciences), in the
single-hole mode. ORM-11372 solutions with concentration of 0.3
(n = 4), 1 (n = 5), 3 (n = 8), 10 (n = 8), and 30 (n = 8) μM were studied.
The extracellular solution contained (in mM) 145 NaCl, 4 KCl, 2 CaCl2,
1 MgCl2, 10 glucose, and 10 HEPES (pH 7.4 with NaOH; osmolarity
adjusted to 305 mOsm). The intracellular recording solution contained
(in mM) 120 KCl, 1.75 MgCl2, 5.37 CaCl2, 4 Na2ATP, 10 EGTA, and
10 HEPES (pH 7.2 with KOH; osmolarity adjusted to 295 mOsm). The
voltage protocol, which was repeated every 10 s, included a 200-ms
step to change the holding potential from −80 to −50 mV, to measure
the leak current, and further depolarization to +20 mV for 2 s,
followed by a repolarization to −50 mV for 2 s. The hERG tail current
was measured as the difference between the peak tail current ampli-
tude during the repolarization step and leak current measurement
step. Subsequently, the voltage dependence of the block was also
assessed, by carrying out depolarization for 4 s, from −80 to +60 mV
in 10-mV steps, before and after the addition of 20-μM ORM-11372
(n = 7). The peak tail current elicited during the 5 s repolarization step
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to −50 mV was measured and plotted against the preceding depolari-
zation step voltage values.
2.8.5 | Action potentials
APs were recorded in spontaneously beating Cor.4U CMs in the cur-
rent clamp using the perforated patch technique and voltage-sensitive
dye (di-4-ANEPPS), in a 96-well plate format. The latter ratiometric
optical measurements were performed on the CellOPTIQ platform at
Clyde Biosciences (Newhouse, UK). The patch-clamp measurements
used the standard extracellular solution at the physiological tempera-
ture and a pipette solution containing (in mM) 122 K-gluconate,
30 KCl, 1 MgCl2, and 5 HEPES (pH 7.2 with KOH; osmolarity adjusted
to 290 ± 3 mOsm) and 0.24 mgml−1 of amphotericin B. The patch-
clamp data shown are from CMs (n = 4) that exhibited ventricular-like
APs, that is, a ratio (time difference between APD30 and APD40/time
difference between APD70 and APD80) >1.5 (Ma et al., 2011).
2.8.6 | Selectivity panel
Radioligand binding assays were performed at Eurofins Cerep SA
(Celle L'Evescault, France), for testing the inhibition capacity of
ORM-11372 (at 10 μM with two replicates), in over 75 targets.
These included receptors (e.g., human A1, A2A, and A3 adenosine
receptors; α1 and α2 adrenoceptors; human β1–β3 adrenergic recep-
tors; human D1, D2S, D3, D4.4, and D5 dopamine receptors; EGF
and VEGF receptors; human M1–M5 muscarinic ACh receptors;
human 5-HT1A, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT4e, 5-HT5A, 5-HT6,
and 5-HT7 receptors), ion channels (5-HT3, Ca
2+, ATP-dependent
potassium channel [KATP], voltage-dependent potassium channel
[KV], small-conductance calcium-dependent potassium channel
[SKCa], Na
+, and Cl−), and transporters (adenosine, noradrenaline,
dopamine, and 5-HT). Follow-up functional studies (with five con-
centrations and two replicates) were performed for 5-HT2A recep-
tors and noradrenaline transporter. Agonism and antagonism at
h5-HT2A receptors was explored in recombinant HEK 293 cells and
intracellular calcium changes were detected using fluorimetry. Nor-
adrenaline uptake was measured by carrying out scintillation cou-
nting of [3H]noradrenaline incorporated into rat hypothalamus
synaptosomes.
2.9 | Design and analysis for isolated heart
preparations and in vivo experiments
2.9.1 | Donor heart procurement
All the human hearts used for this study were obtained after legal
consent and were provided by organ donors in the United States.
The policies for donor screening and consent were the same as
those established by the United Network for Organ Sharing
(OPTN, 2019). Organizations supplying human tissues to AnaBios
follow the standards and procedures established by the US Centers
for Disease Control and Prevention and are inspected biannually
by the Department of Health and Human Services. Tissue distribu-
tion is governed by internal institutional review board (IRB) proce-
dures and was compliance with Health Insurance Portability and
Accountability Act (HIPAA) regulations (Edemekong & Haydel, 2019)
regarding patient privacy. All organ donor transfers to AnaBios are
fully traceable and periodically reviewed by US federal authorities.
In general, AnaBios obtains donor hearts from adults aged
17–60 years old. Though some donors were trauma victims, donors
with the following conditions were excluded: ejection fraction
<45%, HIV, cardiac death, hepatitis B virus (HBV), congenital long
QT time (LQT) syndrome, hepatitis C virus (HCV), LOT syndrome,
methicillin-resistant Staphylococcus aureus (MRSA), downtime
>20 min, ongoing infections, positive blood cultures without treat-
ment, and 48-h result data. Donor hearts from 1 male and 1 female
(both 57 years old, Table S5) were harvested using AnaBios' pro-
prietary surgical techniques and tools and were shipped to AnaBios
via dedicated couriers. Upon arriving at AnaBios, each heart was
assigned a unique identifier number that was reproduced on all rel-
evant medical history files, data entry forms, and
electronic records.
2.9.2 | APs in human ventricular trabeculae
Procedures used for tissue dissection and recording were similar to
those described previously (Page et al., 2016). Briefly, the human
heart was transferred into a dissection vessel containing a cold
(4C), fresh proprietary dissection solution. The heart was
completely submerged into the dissection solution. Ventricular tra-
beculae were dissected and transferred to the recording chamber.
The approach used to record APs is similar to that described by
Page et al. (2016). Briefly, a single tissue was mounted into the
experimental chamber filled with oxygenated Tyrode's external
solution, containing (in mM) 136 NaCl, 4 KCl, 0.5 MgCl2,
12 NaHCO3, 0.35 NaH2PO4, 11.1 dextrose, 1.8 CaCl2, and
10 HEPES (pH 7.4). The temperature of the solution was
maintained at 37C, at a flow rate of 5 mlmin−1. The tissue was
allowed to equilibrate for 30–60 min, while providing stimulation
(3 V, 3 ms) at a frequency of 1.0 Hz. High-impedance borosilicate
microelectrodes were prepared with a tip resistance of 10–20 MΏ,
filled with 3-M KCl. Upon tissue impalement, the membrane poten-
tial was allowed to stabilize (typically, around −85 mV). Tissues
with resting membrane potentials (RMPs) more positive than
−75 mV were rejected. Bipolar stimulation at 1.5× threshold was
applied, and recordings were obtained in the continuous mode with
sampling at 20 kHz, using ADInstruments and LabChart software.
Tissue exclusion criteria included the following: (i) interruption of
perfusion/oxygenation; (ii) absence of APs following stimulation at
baseline; (iii) time frame of drug exposure not respected;
(iv) unstable response to stimulation at baseline; (v) RMP > −75 mV;
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(vi) maximal amplitude of AP (Amax) < 70 mV; and (vii) AP duration
at 90% repolarization (APD90) < 200 or >450 ms. ORM-11372
was evaluated at three concentrations in four ventricular trabeculae
derived from two donor hearts (n = 2, two replicates). Testing con-
centrations were 0.1, 1, and 10 mM. Following the stabilization of
each tissue, APs were collected and assessed for 31 min in the
vehicle control solution (Tyrode with 0.1% DMSO), at stimulation
frequencies of 1 Hz for 25 min, 2 Hz for 3 min, and 1 Hz for
3 min. Following this vehicle control period, three concentrations
of ORM-11372 were applied sequentially and cumulatively. Each
concentration was applied for 31 min with the same stimulation
sequence as in the vehicle controls.
2.10 | Design and analysis of animal experiments
All animal experiments were performed according to European Com-
munity Guidelines for the use of experimental animals and approved
by the Finnish National Animal Experiment Board. Animal studies are
reported in compliance with the ARRIVE guidelines (Percie du Sert
et al., 2020) and with the recommendations made by the British Jour-
nal of Pharmacology (Lilley et al., 2020).
2.10.1 | Selection of animal species
The rat is the most widely used rodent species in toxicology stud-
ies performed for drug development. The Sprague–Dawley rat
strain (RRID:RGD_70508) is commonly used in the rat myocardial
infarction (MI) model (Fishbein, Maclean, & Maroko, 1978). How-
ever, the functional similarity between the Ca2+ handling proteins
(including NCX) in rats (Bassani, Bassani, & Bers, 1994) and human
hearts is rather low. The Ca2+ circulation balance in the guinea pig
and rabbit hearts are more similar to that of a human (Milani-Nejad
& Janssen, 2014). Rabbits and humans are also known to react
similarly to medication; hence, the rabbit was selected as a non-
rodent species.
2.10.2 | Housing and husbandry
Animals were monitored daily by laboratory personnel. If the gen-
eral health status of an animal was significantly worsened, the ani-
mal was killed with an overdose of pentobarbital. Human
endpoints included no spontaneous movements and inability to
drink or eat during the 24-h observation period, massive bleeding,
spontaneous inflammation, missing anatomical features or swelling,
and breathing difficulties. Specific pathogen-free animals were
housed in half-barrier rooms where special protective clothing was
required by personnel. Animal rooms were cleaned regularly three
times per week, and cages and bottles were changed at regular
intervals once a week. The temperature was maintained at
22 ± 2C and humidity at 55 ± 15%. In the light–dark cycle, lights
were kept on from 6:00 a.m. to 8:00 p.m. Body weights of all ani-
mals were measured weekly.
2.10.3 | Randomization and blinding
Randomization was used whenever feasible. Guinea pigs were ran-
domized into vehicle and ORM-11372 groups for in vitro contrac-
tion force measurement from papillary muscle. In haemodynamic
studies involving rabbits, only one study group was used, according
to the 3R principle. Because the experimental set-up involved
ascending doses in one study group, randomization was impossible.
Baseline values were used as controls to reduce variability. How-
ever, the MI rat model required the inclusion of two study groups,
to eliminate the effect of surgical operations. The MI study set-up
enabled the use of randomization. The study duration for
anaesthetized animals is limited; hence, higher doses had to be
administered, which required blinding to be performed in all in vivo
studies. The blinding was not considered relevant, because mea-
sured absolute values and derived parameters are not sensitive to
biased interpretations.
2.11 | In vitro contraction dynamics measurement
Guinea pigs (both sex, body weight ranging 342–565 g, Dunkin
Hartley, M&B A/S, Ry, Denmark) were used in the study. The animals
were housed in solid bottom polycarbonate cages (Makrolon® IV,
385 × 590 × 200 mm) with stainless steel wire mesh lids, up to three
animals of same sex per cage. Autoclaved aspen chips (Tapvei Ky,
Kaavi, Finland) were used as bedding. A commercially available rodent
SDS FD1 (P) SQC pellet diet (Special Diet Services Ltd, Witham,
England) and tap water from the public supply (Espoon vesilaitos,
Espoo, Finland) were available ad libitum in polycarbonate bottles
(800–1,000 ml) with plastic caps (Scanbur A/S, Ejby, Denmark).
Guinea pigs were killed by a blow on the skull and the heart will
be excised. Right ventricular papillary muscle was dissected and rinsed
in ice-cold Tyrode's solution. Thereafter, the papillary muscle was
mounted for the measurement of twitch tension in an organ bath con-
taining modified Tyrode's solution (at 37C) bubbled with carbogen
(95% O2 and 5% CO2). The composition of Tyrode's solution was as
follows (in mM): 135 NaCl, 1 MgCl26H2O, 5 KCl, 2 CaCl22H2O,
15 NaHCO3, 1 Na2HPO42H2O, and 10 glucose at pH 7.3–7.4.
The signal was acquired with a validated acquisition system ACFO
v1.0 (Fision Oy, Finland). The following parameters were measured:
twitch tension (Tw), rest tension (RT), time to peak tension (TTP), and
half relaxation time (HRT). At steady state, 15 twitch tensions were
acquired and averaged was used for statistics.
The baseline twitch tensions were measured after a stabilization
period of 20–40 min. Thereafter, vehicle (1.1% DMSO) or ORM-
11372 in Tyrode's solution was superfused into the cuvette for
15 min, and the effects were measured from the steady-state level.
All experiments were carried out at 37C.
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2.12 | Experimental MI model
Male Sprague–Dawley rats (Harlan, Netherlands B.V.) were housed in
polycarbonate cages (Makrolon IV with stainless steel wire mesh lids).
A maximum of five rats were housed per cage with aspen chip bed-
ding (Tapvei Ky, Kaavi, Finland). Rats had free access to water (twice
filtered, Espoon Vesi) and a rodent diet (SDS RM1 (P) SQC pelleted
diet, Special Diet Services Ltd, Witham, England). The acclimation
period before experiments was at least 5 days. In the MI model, rats
(7–8 weeks, 200–250 g) were randomized into either the MI or sham
group. In this weight range, a rat is considered a young adult, when its
evolution phase is characterized by slow growth and its surgical mor-
tality is lower than that of older animals. Male rats were used to mini-
mize the variability of the cardiac response to several stimuli (Zornoff,
Paiva, Minicucci, & Spadaro, 2009).
Rats were anaesthetized with a combination of ketamine
(Ketalar® 50 mgkg−1, i.p.) and medetomidine (Domitor
250 μgkg−1, i.p.), intubated, and artificially ventilated with air (Ugo
Basile 7025). An MI was induced by the occlusion of the left coro-
nary artery under aseptic conditions (Levijoki, Pollesello, Kaheinen,
& Haikala, 2001; Selye, Bajusz, Grasso, & Mendell, 1960). The left
coronary artery was ligated at a distance of about 2–3 mm from
the origin of the aorta with a silk suture, and the heart was
repositioned into the chest. After ligation, the wound was closed
carefully. The muscle layer was closed with soluble stitches and
skin layers with insoluble stitches, followed by a partial reversal of
anaesthesia via the intraperitoneal administration of atipamezole
(Antisedan® 0.3–1 mgkg−1, i.m.). The trachea tube was removed,
and the trachea and underlying muscle and skin layers were closed
immediately. To prevent dehydration, rats were subcutaneously
administered with 5 ml of 0.9% NaCl. After surgery, rats were
given analgesia with buprenorphine for at least 2 days
(0.05 mgkg−1, s.c. twice a day). For sham-operated rats, the same
procedure was performed, without ligation. Rats were analysed for
7 days after the MI, for signs of severe acute heart failure such as
oedema or breathing difficulties.
2.13 | Haemodynamic measurements of
anaesthetized animals
All animals were given multiple ascending infusion doses of ORM-
11372; blinding was not possible. Systemic BP (SP) and left ventricular
pressure (LVP) values were measured with pressure transducers
(SP for femoral artery: Isotec, Hugo Sachs Elektronic, Germany; a min-
iature pressure transducer Mikro-Tip transducer SPR-249, Millar
Instruments was inserted into the left ventricle via the right carotid
artery). The signal was amplified (DC-bridge amplifier type 660, Hugo
Sachs Elektronik, Germany), digitized (I/O connector block type SCB-
68, National Instruments, USA), recorded, and analysed (IHME 1.0.9,
Fision Ltd, Finland). Left ventricular inotropic effect (LV + dP/dtmax),
relaxation (LV − dP/dtmin), and HR values were analysed from
LVP signals.
At the end of the haemodynamic experiments, rats and rabbits
were killed with an overdose of pentobarbital. Small laboratory equip-
ment (forceps, scissors, scalpels, etc.) were sterilized in the glass bead
sterilizer at 300C for 10 seconds.
The BP waveform was measured continuously in milliseconds.
Blinding was not considered relevant, because the absolute value was
not sensitive to biased interpretations, and all parameters are derived
from of them.
2.13.1 | Haemodynamics in MI rats
Haemodynamics were assessed 7 days after the MI (n = 6) or
sham operation (n = 6) as follows. Rats were anaesthetized with
isoflurane (2.25–2.5%, Baxter) in carbogen (95% O2 and 5% CO2)
and nitrous oxide (1:1), using a small rodent ventilator (Ugo Basile
7025, 10 mlkg−1, 60 strokesmin−1). The rats were infused with
0.9% NaCl in the carotid vein at the stabilization and baseline
levels. ORM-11372 was administered into MI (n = 6) and sham
(n = 6) rats in ascending infusion doses of 1.7, 17, 167, and
417 μgkg−1min−1. Infusions were administered into the jugular
vein of MI rats at the infusion rate of 5 mlkg−1h−1 (Terumo TE-
311, Belgium). Doses were selected based on a pilot study with
healthy rats (Figure S20). The total number of animals in the study
was 12 + 2, due to the replacement of two MI rats. One MI rat
died while administering anaesthesia, as infarcted animals are sensi-
tive to anaesthesia, and another MI rat was excluded due to the
dosing error indicated by the bioanalysis of plasma samples
(no ORM-11372 concentration observed in plasma).
After haemodynamic assessments, the anaesthetized rats were
killed with an overdose of pentobarbital (2 ml of Mebunat® vet
60 mgml−1 per rat). The entire heart of each animal was fixed in
buffered 4% formaldehyde solution, trimmed, processed, and
embedded in paraffin. The hearts were cut horizontally at three
different levels: apex, mid part, and base. Sections (4 μm) were cut
from each level stained with haematoxylin and eosin, for general
histopathological analysis. Infarct sizes were determined using
Picrosirius Red staining as an indicator of cardiac fibrosis, and the
size was measured using AnalysisPro software. The infarct area
was calculated as the per cent of fibrotic tissue in the total myo-
cardial area (mean of three levels).
2.13.2 | Haemodynamics in rabbits
Male New Zealand white rabbits (Harlan, Netherlands B.V.) were
housed individually in polycarbonate cages (Scanbur Number 8 plastic
cages with stainless steel door) with aspen bedding (Aspen Bricks M,
Tapvei Ky, Kaavi, Finland). The acclimation period before experiments
was at least 21 days. Rabbits weighing 2.0–2.3 kg (age 10–12 weeks)
were used for haemodynamically assessing ORM-11372
(no randomization, baseline values as own control). The diet provided
to rabbits was SDS Stanrab (P) SQC pelleted (Special Diet Services
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Ltd, Witham, England). Water was provided ad libitum in polycarbon-
ate bottles (750 ml).
Rabbits (n = 5) were sedated with i.v. (marginal vein) diazepam
(2 mgkg−1, Diapam®, Orion Pharma). Anaesthesia was induced with
i.v. S-ketamine (10–20 mgkg−1 Ketanest-S®, Pfizer) and maintained
with S-ketamine i.v. infusion (15–80 mgkg−1h−1). Animals were
placed on a heating table (+38C), and tracheas were cannulated. Rab-
bits were ventilated via a rodent ventilator (Ugo Basile 7025, Hugo
Sachs Elektronik, Germany; respiratory volume 10 mlkg−1, 30 stro-
kesmin−1 for rabbits). ORM-11372 was infused into the jugular vein
at an infusion rate of 10 mlkg−1h−1 (Terumo TE-311, Belgium), at
infusion doses of 17, 167, and 833 μgkg−1min−1.
2.14 | Blood sampling for bioanalysis
At the end of each infusion process, blood samples (300–500 μl) were
added to a chilled EDTA polypropylene tube (CapiJect®, Terumo) and
centrifuged (1431 x g, 10 min, at 4C). Plasma was immediately frozen
in polypropylene tubes and stored at −20C. ORM-11372 was
extracted from plasma samples using a liquid–liquid extraction process
and analysed using LC–MS/MS (Agilent Technologies series 1100 LC
system and a Sciex LC–MS/MS API 4000 MS). The lower limit of
quantification for the plasma concentration of ORM-11372 was
32.0 ngml−1. Plasma protein binding in ORM-11372 was assessed
using the TRANSIL High Sensitivity kit, as per the manufacturer's
instructions (Sovicell, GmbH, Germany).
2.15 | Data and statistical analysis
Results from the experiments with human trabeculae were
expressed as APs at each selected frequency. For each frequency
tested, the last 30 APs acquired at the end of the period were
averaged for vehicle controls, for each ORM-11372 solution with a
certain concentration. Analysis at 1 Hz included only the last
30 APs from the initial 25 min incubation period. The following AP
parameters and pro-arrhythmia variables were analysed offline
upon the completion of recordings: RMP (mV), AMAX (mV), AP
duration at percent repolarization (APD30, APD50, APD90) (ms),
short term variability analysis of AP duration (STV), triangulation
(APD90-APD30).
STV was calculated as the beat-to-beat variability in repolariza-
tion from APD90 Poincare plots over a 30 sec duration. STV for
APD90 was calculated as follows: STV = jAPDn+1−APDnj/(30×√2),
where APD (n) and APD(n+1) are the APDs for the nth AP and the fol-
lowing AP respectively.
The effects of ORM-11372 were quantified relative to the data
collected during the vehicle control period. Threshold values for
changes over the baseline control for APD30, APD50, APD90, trian-
gulation, and STV at 1 and 2 Hz pacing frequencies have been deter-
mined in a previous validation study (Page et al., 2016). Results are
expressed as mean ± SEM.
The data and statistical analysis of in vitro and in vivo studies
comply with the recommendations for experimental design and
analysis in pharmacology (Curtis et al., 2018). Data were analysed
statistically only when the number of independent samples was
5 or more. A P-value of <0.05 was considered to be significant.
Two-way repeated measures ANOVA were used for the analysis of
the papillary muscle and myocardial infarction models. One-way
repeated measures ANOVA was used for the rabbit haemodynamic
study. The Sidak post hoc test was run only if the F-value was sta-
tistically significant, and there was no significant variance in homo-
geneity. Data are presented as mean ± SEM. Prism 8.0.2
(GraphPad Software Inc., San Diego, CA, USA; RRID:SCR_002798)
was used for statistical analysis.
2.16 | Materials
2.16.1 | Study substance
ORM-11372 was synthetized by Orion Pharma. To perform in vitro
experiments, ORM-11372 was dissolved in DMSO, to obtain a
10-mM stock solution. Spiking solutions were prepared daily by dilut-
ing the stock solution with DMSO and used to prepare the final drug
solutions with certain concentrations by diluting them with extracellu-
lar solutions (the vehicle concentration was either 0.1% or 0.3%). The
solubility of ORM-11372 in saline and 5% glucose solutions used for
in vivo dosing was 5.3 and 5.4 mgml−1 respectively. ORM-11372 was
soluble in 10–100 μgml−1 of phosphate buffer (at pH 7.4). ORM-
11372 has the following drug like properties: The number of hydro-
gen bond acceptors is 1 (<10) and donors is 3 (<5), MW of free base is
282 (<500), and the predicted logP value is less than 5 (ADMET Pre-
dictor: 3.95, MOE: 3.413, and QikProp: 3.974).
2.16.2 | Other chemicals
The suppliers of other materials used are indicated as follows: Isoflurane
(Forane®, Baxter), atipamezole (Antisedan, Orion Pharma), med-
etomidine (Domitor®, Orion Pharma), ketamine (Ketalar, Pfizer Oy Ani-
mal Health), lipofectamine (Invitrogen, USA), hygromycin B (Invitrogen),
and buprenorphine (Temgesic®, INDIVIOR UK Ltd). All other chemicals
and cell culture media were obtained from Sigma-Aldrich.
2.16.3 | Cell lines and cell culture
NCX 1.1 was cloned, and plasmid was constructed by Orion Pharma
Sf9 cells (ATCC), hiPSC-derived CMs (Cor.4U CMs from Ncardia, Ger-
many; Detachin™ Cell Detachment Solution, Genlantis), HEK 293 cells
and IMR-32 human neuroblastoma cells (ATCC), CHO cells hERG1a
(KCNH2; Sophion Biosciences, Denmark), CHO cells human 5-HT2B
receptors (Euroscreen, Belgium), and hSCN5A plasmid (OriGeneTech-
nologies Inc., Rockville, MD, USA).
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2.17 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in the IUPHAR/BPS Guide to PHARMACOL-
OGY (http://www.guidetopharmacology.org) and are permanently
archived in the Concise Guide to PHARMACOLOGY 2019/20
(Alexander, Christopoulos et al., 2019; Alexander, Fabbro et al., 2019;
Alexander et al., 2019a, 2019b; Alexander, Mathie et al., 2019).
3 | RESULTS
3.1 | ORM-11372 inhibits human and rat NCX
activity
ORM-11372 concentrations dependently inhibited the increase in
intracellular calcium in the insect cell line expressing human NCX1.1.
The insect cell line was used as the screening assay. The IC50 for the
inhibition of NCX in the reverse mode was 6.2 ± 0.4 nM.
The effects of ORM-11372 for NCX was subsequently studied
using the whole-cell patch-clamp technique in human iPS-derived
CMs (hiPSC-CMs; Figure 3) and rat ventricular CMs (Figure 4). The
solutions and experimental protocol used to measure the bidirectional
NCX current (INCX) were identical for both preparations. As shown in
Figure 3a, the current was recorded in response to repetitive voltage
ramp pulses first in a K+-free bath solution after blocking Na+, Ca2+,
K+, and Na+/K+ pump currents, to yield the baseline, and during the
addition of ORM-11372. Finally, when the highest concentration of
ORM-11372 had reached a steady state, 10-mM NiCl2 was added to
completely block INCX. Examples of individual trace currents under dif-
ferent conditions are shown for a hiPSC-CM in Figure 3b and for a rat
CM in Figure 4a. ORM-11372 decreased both the outward and
inward currents. The IC50 values for the outward and inward INCX (i.e.,
the Ni2+-sensitive current) of hiPSC-CMs were 4.8 and 5.6 nM
respectively (Figure 3c). In rat primary ventricular CMs, the magnitude
of outward INCX (the reverse mode) with an IC50 of 11.3 nM
(Figure 4b) was reduced by ORM-11372, in a concentration-
dependent manner. It was difficult to record inward INCX (the forward
mode) from rat CMs. We therefore altered the experimental condi-
tions to enhance its magnitude (see Section 2). At 10 nM, the approxi-
mate IC50 on the outward INCX, ORM-11372 inhibited inward INCX by
53.8 ± 3.9%.
F IGURE 3 Effect of ORM-11372 on the bidirectional INCX of human-induced pluripotent stem cell (iPSc)-derived cardiomyocytes. (a) The
experimental time course included a ramp voltage protocol to be repeated every 20 s. The current traces at the labels (A: control; B and C: in the
presence of 3- and 30-nM ORM-11372; and D: when INCX is fully blocked by 10-mM NiCl2) are shown in (b) enlarged and superimposed (with the
voltage protocol below) images. (c) The concentration–response curve for ORM-11372 on the outward (3 nM, n = 4; 10 nM, n = 6; 30 nM, n = 4;
and 100 nM, n = 3) and inward (3 nM, n = 4; 10 nM, n = 4; 30 nM, n = 3; and 100 nM, n = 2) INCX was determined at +60 and −100 mV
respectively. The IC50 values are calculated using non-linear regression. Data shown are individual values; n refers to the number of iPS derived
cardiomyocytes
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3.2 | Comparison with known NCX inhibitors
Further confirmation of the inhibitory effects of ORM-11372 was
sought in the hNCX1 fluorescence calcium flux assay available at
Charles River. In experimental conditions increasing intracellular cal-
cium (by the presence of thapsigargin and FCCP) and eliciting NCX
forward mode activity (switching from Na+-free to Na+-containing
buffer), ORM-11372 concentration-dependently inhibited the calcium
efflux signal (Figure 5a) with an IC50 of 142 and 164 nM (0.3% and
1% DMSO, respectively; NS). The hNCX1 antagonist of five other
compounds was also assessed in this assay. ORM-11372 was the
most potent inhibitor (Figure 5b) followed by ORM-10962 (Figure 5c),
ORM-10103, SEA0400, KB-R7943, and lastly SN-6 whose IC50
appears >100 μM.
3.3 | Selectivity
The functional selectivity of ORM-11372 towards the L-type Ca2+
channel was first tested with the IMR-32 neuroblastoma cell line,
using fluorometric images of intracellular changes in calcium levels.
Depolarization of undifferentiated IMR-32 cells by KCl addition
induced an increase in intracellular calcium levels, which can be
suppressed by pre-incubation with verapamil or the
1,4-dihydropyridine nicardipine (Sher et al., 1988). L-type calcium
channels mediated changes in intracellular calcium levels, and these
were concentration-dependently inhibited by ORM-11372 with an
IC50 of 6.1 μM. Further electrophysiological studies were then per-
formed with hiPSC-CMs and rat ventricular CMs. The inward ICaL was
reduced by 1-μM ORM-11372 at 0 mV by 14.1% in hiPSC-CMs
(Figure 6a), and a 7.8% inhibition was observed in rat CMs
(Figure S16A,B; individual inhibition values at 1 and 10 μM are shown
inTables S3 and S4, respectively). However, when rat ventricular CMs
were exposed to ORM-11372 at a concentration of 10 μM, ICaL was
significantly decreased (Figure S16C). ICaL inhibition exhibited voltage
dependency, which was greater (59–69% vs. 36–39%) at more nega-
tive activating test potentials (−35 to −20 vs. 0 to 40 mV).
The effect of ORM-11372 on other cardiac ion channel currents
was investigated. The reduction in the human alpha subunit of a
potassium ion channel (KV11.1) current (IhERG) was initially examined
F IGURE 4 The effect of ORM-11372 on the reverse sodium–calcium exchanger (NCX) current measured in rat ventricular cardiomyocytes is
presented in panel (a). The top left panel (a) shows the voltage protocol applied during experiments: The I–V (current–voltage) relationship of the
Na+/Ca2+ exchanger current was measured through the use of ramp pulses at 20-s intervals. The ramp pulse initially lead to depolarization from
the holding potential of −40 to 60 mV, at a rate of 100 mVs−1, followed by hyperpolarization to −100 mV, and depolarization back to the
holding potential. The middle panel illustrates original current records in the absence (control) and presence of 10-nM ORM-11372 and after
applying 10-mM NiCl2. The Ni
2+-sensitive current traces clearly show that 10-nM ORM-11372 effectively inhibits the reverse NCX current.
Example of the I–V (current–voltage) relationship of the Na+/Ca2+ exchanger current is shown in panel (b). The magnitude of reverse NCX current
measured at 20 mV was reduced by ORM-11372 in a concentration-dependent manner in rat ventricular cardiomyocytes in panel (c). The
concentration–response curve for ORM-11372 on the outward (n = 5) and inward (n = 3) INCX was determined at +60 and −100 mV respectively.
The IC50 value for the outward INCX current is calculated using non-linear regression. Data shown are individual values; n refers to the number of
rat primary ventricular cardiomyocytes
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F IGURE 6 Effects of ORM-11372 on various cardiac ion channel currents of induced pluripotent stem cell (iPSc)-derived cardiomyocytes
(illustrative figures in panels a–c) and contraction force in guinea pig papillary muscle (panels d–g). (a) The L-type ICa was minimally inhibited by
1-μM ORM-11372. (b) The concentration-dependent inhibition of KV11.1 current by 0.3-, 3-, 10-, and 30-μM ORM-11372 and (c) NaV1.5 current
by 1-, 3-, 10-, and 30-μM ORM-11372. The applied voltage protocols are shown as insets. The traces marked by asterisk in (a) and (c) are the
currents in the presence of 100-nM nitrendipine and 2-mM lidocaine respectively. (d) ORM-11372 increased twitch tension, which indicates
increased SR load. (e) ORM-11372 did not increase resting tension, that is, no increase in diastolic calcium. (f) ORM-11372 did not affect time to
peak demonstrating that calcium release from ryanodine receptors is normal. (g) Also, half relaxation time was unchanged showing that SERCA
function remains normal. Data shown are means ±SEM (n = 5) and individual values with red and blue circles for female and male respectively.
Two-way ANOVA followed by Sidak's multiple comparison test. *P < 0.05, signficant effect of ORM-11372; two-way ANOVA followed by Sidak's
multiple comparison test. Pacing rate 1 Hz. Temperature 37C
F IGURE 5 The effects of selected NCX
inhibitors were tested on the forward mode in
confirmatory hNCX1 inhibition assays in HEK293
cells. In (a), data shown are means ± SEM from
n=5 assays. In (b), experimental records show the
effects of increasing concentrations of ORM-
11372 (0.001, 0.003, 0.01, 0.03, 0.1, 0.3 and 1μM)
and in (c), of ORM-10962 (0.03, 0.1, 0.3, 1, 3 and
10μM) to decrease Ca2+ efflux (downward
deflection) from control conditions (blue trace).
Each assay derived from one plate with four
replicates per plate
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using stably expressing cells on an automated patch-clamp instrument
and then with the manual patch-clamp. ORM-11372 concentration-
dependently inhibited IhERG (Figure 6b); IC50 values were 19.2 and
10.0 μM, using the automated and manual patch-clamp methods
respectively (Figure S15A). ORM-11372 significantly altered the volt-
age dependency of the IhERG activation curve (Figure S15C) and dis-
played significant voltage-dependent blockage. While IhERG inhibition
was minimal at −30 and −20 mV, inhibition increased markedly at
−10 and 0 mV and reached a steady state between 10 and 60 mV,
that is, at potentials where the channels were fully activated
(Figure S15D). Additionally, ORM-11372 concentration-dependently
inhibited the human voltage-gated sodium channel, alpha subunit
5 (NaV1.5) current (Figure 6c), with an IC50 value of 23.2 μM.
ORM-11372 increased twitch tension compared with values in
the vehicle group (Figure 6d), but did not increase rest tension
(−8 ± 2% vs. −10 ± 1% in vehicle, Figure 6e) and did not affect time
to peak (−4 ± 1% vs. −5 ± 2% in vehicle, Figure 6f) or the half relaxa-
tion time (Figure 6g).
The selectivity profile of ORM-11372 was additionally evaluated
in binding assays for a diverse panel of targets. While minor effects
such as those for the Na+/K+-ATPase or ryanodine receptor (11% and
15% inhibition) were seen, with a screening concentration of 10 μM,
specific ligand-binding inhibition was significant (i.e., >50%) at
peripheral benzodiazepine receptor, 5-HT2A and 5-HT2B receptors,
and at the noradrenaline transporter. The latter three targets were
studied functionally. The uptake of noradrenaline into rat hypothala-
mus synaptosomes was inhibited by ORM-11372 in a concentration-
dependent manner; the IC50 value was 1.7 μM. Neither agonism nor
antagonism was seen with ORM-11372 (maximum concentration:
10 μM) at 5-HT2A receptors. Similarly, no agonist activity was evident
at 5-HT2B receptors but 10-μM ORM-11372 did moderately inhibited
(38%) the 5-HT2B receptor-mediated increase in intracellular calcium
evoked by 10-nM 5-HT.
3.4 | Human ventricular trabeculae
ORM-11372 caused no significant changes in APD30, APD50, and
APD90 values up to a concentration of 10 μM, at both 1- and 2-Hz
pacing frequencies. However, there was a trend in the reduction in
APD, particularly APD30, at 1 Hz (Figure S17); this seemingly contrasts
with the significant shortening of hiPSC-CM APD by ORM-11372
(at 0.1 or 0.3 μM; Figure S18). As expected, the effect of the positive
control (0.1-μM dofetilide) was observed in trabeculae tested with
ORM-11372 (Figure 7); individual values are shown in Figure S17
(Page et al., 2016; Qu et al., 2017). Moreover, ORM-11372 showed
no effects on STV and triangulation, two pro-arrhythmia markers that
are used to identify pro-arrhythmic risk (Page et al., 2016; Qu
et al., 2017), at a pacing rate of 1 or 2 Hz, at any tested concentration
(Individual values in Figure S19). However, the addition of 0.1-μM
dofetilide to the trabeculae tested with ORM-11372 increased STV
and triangulation (Figure S18). Taken together, these data clearly sug-
gest that ORM-11372 can be classified as devoid of pro-
arrhythmic risk.
3.5 | In vivo haemodynamics in rat MI model
Infarcted areas were 14.5 ± 1.8% and 1.1 ± 0.6% in the MI and sham-
operated groups respectively (Figure S20). Percentage changes are
calculated from absolute values. Infarctions caused the baseline of
positive inotropic effect and relaxation to be reduced by 38% and
23% respectively. Heart rates (−3%) were unaffected, but systemic
arterial pressure reduced by 20%.
In MI rats, ORM-11372 improved maximally positive inotropic
effect by 18 ± 6% and by 31 ± 6% in sham rats (Figure 8a). Maximal
effects were observed at the highest infusion dose of
417 μgkg−1min−1, corresponding to free plasma concentrations of
F IGURE 7 Effects of ORM-11372 on action potentials (APs) in human ventricular trabeculae (n = 2, two replicates). (a) Typical APs recorded
from a human ventricular trabecula at a pacing rate of 1 Hz in the presence of vehicle (V) control and after exposure to ORM-11372 (0.1, 1, and
10 μM) and 0.1-μM dofetilide (Dof) (the positive control). (b) Mean changes in APD90, triangulation, and short-term variability analysis of AP
duration (STV) values were in cadence when trabeculae were incubated with ORM-11372 and Dof at 1 and 2 Hz. Notably, the effects of ORM-
11372 and Dof on APD90/triangulation activity and STV are plotted on a separateY-axis. Data shown are individual values; n refers to the
number of human hearts, and replicates refer to the number of trabeculae in the same heart
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6.7 ± 2.5 and 4.9 ± 0.4 nM. At the lowest infusion dose of
1.7 μgkg−1min−1, ORM-11372 improved relaxation levels in the MI
group by 24 ± 2% (Figure 8b). ORM-11372 maximally reduced the HR
in the MI group but not in the sham rats (Figure 8c). ORM-11372 had
no effect on the systemic arterial BP, in the MI or sham groups
(Figure 8d).
3.6 | In vivo haemodynamics in rabbits
ORM-11372 induced a 35 ± 8% (calculated from absolute values) sta-
tistically significant increase in cardiac contractility in healthy rabbits,
at an infusion rate of 833 μgkg−1min−1 (Figure 9a). At rates of
17–833 μgkg−1h−1, ORM-11372 infusions did not have any effects
on cardiac relaxation (Figure 9b), HR (Figure 9c), or systolic BP
(Figure 9d) in healthy rabbits.
4 | DISCUSSION
Although the first NCX inhibitor, exchanger-inhibiting peptide (XIP),
was a peptide, it enabled us to study the role of NCX under physiolog-
ical and pathological conditions in cells and isolated tissues (Hobai
et al., 1997). However, it took 20–30 min for NCX to be inhibited; it
also inhibited SERCA and PMCA (Enyedi & Penniston, 1993). The
next important step was the isolation and characterization of the
naturally occurring NCX inhibitor (intrinsic factor-inhibiting NCX
[NCXIF]) (Hiller, Shpak, Shavit, Shpak, & Khananshvili, 2000). It was
the first specific, cell membrane-penetrating NCX inhibitor (Shpak,
Hiller, Shpak, & Khananshvili, 2003), but the structure of NCXIF was
not published.
The first generation compounds (Table S1) that were specifically
targeted to inhibit NCX were used as pharmacological tools to assess
the inotropic mechanisms of various drugs like cardiac glycosides
(Ruch, Nishio, & Wasserstrom, 2003; Tanaka et al., 2007) and insulin
(Hsu et al., 2006). The potency of the first generation NCX inhibitors
was modest, and selectivity between NCX and other membrane cur-
rents was poor, especially towards the L-type Ca2+ current (Birinyi
et al., 2005). SEA0400 was positively inotropic in rats, but not in rab-
bits (Farkas et al., 2008), in which the role of NCX is similar to that of
humans. For the second-generation NCX inhibitor ORM-10103
(Koskelainen et al., 2003), the selectivity between NCX and other cur-
rents was improved (Kormos et al., 2014). The following molecule
ORM-10962 (Otsomaa et al., 2004) exhibits even better potency and
more improved solubility (Kohajda et al., 2016). Discovery of ORM-
11372 created the ground for the third-generation NCX inhibitors
with a unique structure combined with improved drug-likeness.
In this paper, we show that ORM-11372 inhibited NCX 1.1
reverse and forward mode currents with a similar potency in both
human iPS and rat CMs. Furthermore, the inhibition of human and rat
NCX 1.1 currents was shown to be of the same magnitude (IC50 was
5 vs. 10 nM). NCX 1.1 expression has been demonstrated in iPS-CMs
F IGURE 8 Effects of ORM-11372 on haemodynamics in isoflurane-anaesthetized rats, 7 days after the induction of myocardial infarction
(MI, n = 6) or in sham rats (n = 6). Effects on the left ventricular contractility (LV + dP/dtmax) are shown in panel (a), along with values for
(b) relaxation (LV − dP/dtmax), (c) heart rate, and (d) systolic arterial BP. Data shown are individual values with means ± SEM; n refers to number of
rats. *P<0.05, significantly different from base line (BL); two-way repeated measures ANOVA followed by Dunnett's post hoc test
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(Fine et al., 2013; Kodama et al., 2019). To our knowledge, the pres-
ence or absence of the other NCX subtypes in hiPS has not yet been
reported. Furthermore, NCX 1.1 expression is tissue specific (Lee, Yu,
& Lytton, 1994); it can be stated that ORM-11372 is a potent and
selective NCX 1.1 inhibitor compared with other cardiac ion channels,
but NCX subtype selectivity is unknown. NCX has specialized role in
ECC. Cell-specific regulation of NCX1 expression is due to a cardiac
specific promoter, which leads to very high expression of NCX 1.1 in
cardiac tissue (Nicholas et al., 1998). Hence, the effect of ORM-
11372 is cardiac specific. In earlier studies, it was speculated that pos-
itive inotropic effects could be attributable to the asymmetrical block-
ing of NCX (Oravecz et al., 2018). ORM-11372 induced positive
inotropy in healthy and MI rats, although it symmetrically inhibited
both inward and reverse NCX currents. In rat plasma, the effective
free concentration range of ORM-11372 was from 4 to 300 nM
(Figure S20), corresponding to the NCX inhibition range of IC25 to
IC80 in rat CMs (Figure 4c). ORM-11372 induced positive inotropy
even in vivo, in the healthy rabbits, in contrast to SEA0400 (Farkas
et al., 2008). The fact that the ORM-11372 is more than 10 times
more potent than SEA0400, as a NCX inhibitor, explains its positive
inotropic effect in rabbits. This was also confirmed in hNCX1–HEK
assay (Figure 5). ORM-11372 increased twitch tension (Figure 6d),
which indicates increased SR load. Furthermore, unlike SEA0400,
ORM-11372 inhibited NCX 1.1 current selectively, and other CM cur-
rents were negligibly inhibited.
ORM-11372 had no effect on relaxation levels in normal rats and
rabbits, but at the lowest dose, it improved relaxation levels in MI rats.
Rat haemodynamics is subject to limitation of the fact that rat CM
relaxation depends less on NCX and more on the other Ca2+ handling
mechanisms. An earlier study conducted in vitro using SEA0400
showed that NCX inhibition caused deterioration in transient Ca2+
levels, but not mechanical relaxation (Szentandrassy et al., 2008). An
ex vivo study using rat isolated perfused hearts with artificial ionic
modification, demonstrated that NCX inhibition also depressed
mechanical relaxation levels (Chen et al., 2012). However, it must be
emphasized that the earlier studies were performed using the weaker
and less selective inhibitor SEA0400 (Table 1), under artificial condi-
tions. ORM-11372 did not affect relaxation in guinea pig papillary
muscle (Figure 6g) or in rabbits in vivo, because of the activation of
compensatory Ca2+ handling mechanisms in CMs, as increased intra-
cellular Ca2+ levels enhance SERCA and/or PMCA activity. Further-
more, ORM-11372 had no effects on resting tension (Figure 6e)
indicating no increase in diastolic calcium. ORM-11372 did not either
affect time to peak (Figure 6f), which demonstrated that calcium
release from ryanodine receptors is normal. Our findings are in line
with the study using NCXIF. Haemodynamic assessments in the present
study were made only in male rats and rabbits, which might introduce
potential bias due to sex differences. Our results with human trabeculae
and guinea pig papillary muscle did not show any differences between
sexes, although the number of experiments are low. However, calcium
F IGURE 9 Effects of ORM-11372 on haemodynamics in S-ketamine-anaesthetized rabbits (n = 5). The effects on (a) left ventricular
contractility (LV + dP/dtmax), (b) left ventricular relaxation (LV − dP/dtmax), (c) heart rate, and (d) systolic arterial BP are shown. Data shown are
individual values with means ± SEM; n refers to the number of rabbits. *P<0.05, significantly different from base line (BL); one-way repeated
measures ANOVA followed by Dunnett's post hoc test
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handling activity and NCX expression level in CMs have been shown to
vary with sex, age and regional expression of NCX (Janczewski &
Lakatta, 2010). Therefore, the role of NCX in calcium handling between
sexes should be systematically further explored.
ORM-11372 selectively inhibited INCX over the Kv11.1 current
and provided a safety margin (ratio ≥2,000) of well beyond 30-fold,
which was considered adequate for ensuring an acceptable degree of
safety from arrhythmogenesis (Redfern et al., 2003). This selectivity
was also confirmed in human ventricular tissue. Thus, ORM-11372
can be classified as being non-pro-arrhythmogenic in humans.
Although the NCX current seems to be crucial for beat genera-
tion (Groenke et al., 2013), even a small NCX current is enough to
maintain the heart beat (Gao et al., 2013). In the present study,
ORM-11372 had no effects on HR in vivo in rats or rabbits, and up
to 80% NCX can be inhibited without any effects on the HR
(Figure S20). In vascular arterial cells, NCX contributes to the mainte-
nance of the myogenic tone (Zhang et al., 2010). In a manner similar
to SEA0400 (Yatabe et al., 2015), ORM-11372 had no effects on
systolic BP. These pharmacological properties resulted in unique posi-
tive inotropic effects without the risk of hypotension, increase in HR,
or impairment of left ventricular relaxation.
During the discovery of ORM-11372, multiple iterative DMTA
cycles (Design, Make, Test, Analyse) of optimization (Andersson
et al., 2009) were performed in compliance with the 3R principles,
using the protein- and cell-based in vitro methods, before selecting of
the compounds for in vivo studies. Group size was optimized but was
large enough to obtain reliable results. Animals were also allowed to
become habituated to the procedures, and the necessary analgesia
was used. Rats and rabbits were selected to ensure similar responses
and improved prediction capabilities from in vitro to in vivo studies,
which ultimately would be translated into better efficacy and safety in
human studies. To improve pharmacokinetic and pharmacodynamic
analyses, the plasma levels of ORM-11372 were monitored at the end
of each pharmacodynamic experiment.
A critical feature of the ORM-11372 scaffold was the bridged ani-
line structure with hydrogen bond formation between the A- and B-
ring systems (Figures 1 and 2). The first- and the second-generation
NCX inhibitors lack this hydrogen bond donor in their scaffold. Fur-
thermore, the activity of the ORM-11372 series exhibited better
potency in the screening assay than the known NCX inhibitors
(Tables S1 and S2). This indicates that an additional specific binding
interaction was identified between the ligand and the NCX protein.
However, the finding remains speculative due to the lack of other
experimental evidence, for example, protein–ligand crystal structure.
The crystal structure of the mammalian NCX and its splice variants
are still unavailable, though the crystal structure of the NCX protein
of archaebacterial Methanococcus jannaschii has been published in
2012 (Liao et al., 2012). There are known structural differences
between the prokaryotic and eukaryotic NCX proteins that might lead
to differences in the potential binding pockets and selectivity (John,
Liao, Jiang, & Ottolia, 2013; Khananshvili, 2014). Thus, evidence
regarding the binding pocket for ORM-11372, as well as for the other
NCX inhibitors is yet to be provided.
In conclusion, ORM-11372 is the first in a class of the third gen-
eration of NCX 1.1 inhibitors with a unique scaffold and improved
profile. ORM-11372 is the most potent and selective NCX 1.1 inhibi-
tor decribed so far. ORM-11372 selectively inhibited cardiac NCX 1.1
currents and induced positive inotropic effects in healthy and MI rats,
as well as in rabbits. ORM-11372 exhibited a better haemodynamic
profile and similar positive inotropic effects, as compared with dobu-
tamine, but did not cause an increase in HR or decrease in systolic
BP. Interestingly, at a low dose, ORM-11372 improved relaxation in
the MI model. Studies involving human tissues support the classifica-
tion of ORM-11372 as a non-pro-arrhythmic inhibitor of NCX. Thus,
ORM-11372 can be used as a research tool in further studies of the
role and function of NCX1.1 in vitro and in vivo.
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